South Korea · Delayed Price · Currency is KRW REYON Pharmaceutical Statistics
Total Valuation
KRX:102460 has a market cap or net worth of KRW 205.05 billion. The enterprise value is 414.39 billion.
| Market Cap | 205.05B |
| Enterprise Value | 414.39B |
Important Dates
The next estimated earnings date is Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KRX:102460 has 18.34 million shares outstanding. The number of shares has decreased by -0.17% in one year.
| Current Share Class | 18.34M |
| Shares Outstanding | 18.34M |
| Shares Change (YoY) | -0.17% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 81.15% |
| Owned by Institutions (%) | 3.09% |
| Float | 2.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.41 |
| PB Ratio | 0.93 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 140.77 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 215.83, with an EV/FCF ratio of -64.16.
| EV / Earnings | -13.98 |
| EV / Sales | 2.84 |
| EV / EBITDA | 215.83 |
| EV / EBIT | n/a |
| EV / FCF | -64.16 |
Financial Position
The company has a current ratio of 0.56, with a Debt / Equity ratio of 0.98.
| Current Ratio | 0.56 |
| Quick Ratio | 0.29 |
| Debt / Equity | 0.98 |
| Debt / EBITDA | 930.13 |
| Debt / FCF | -33.46 |
| Interest Coverage | -2.39 |
Financial Efficiency
Return on equity (ROE) is -12.60% and return on invested capital (ROIC) is -7.27%.
| Return on Equity (ROE) | -12.60% |
| Return on Assets (ROA) | -4.09% |
| Return on Invested Capital (ROIC) | -7.27% |
| Return on Capital Employed (ROCE) | -9.81% |
| Weighted Average Cost of Capital (WACC) | 6.04% |
| Revenue Per Employee | 331.66M |
| Profits Per Employee | -67.35M |
| Employee Count | 448 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 2.72 |
Taxes
In the past 12 months, KRX:102460 has paid 5.02 billion in taxes.
| Income Tax | 5.02B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.18% in the last 52 weeks. The beta is 0.56, so KRX:102460's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -0.18% |
| 50-Day Moving Average | 10,595.20 |
| 200-Day Moving Average | 11,126.50 |
| Relative Strength Index (RSI) | 74.46 |
| Average Volume (20 Days) | 36,987 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:102460 had revenue of KRW 145.93 billion and -29.63 billion in losses. Loss per share was -1,616.00.
| Revenue | 145.93B |
| Gross Profit | 37.24B |
| Operating Income | -31.56B |
| Pretax Income | -24.62B |
| Net Income | -29.63B |
| EBITDA | 232.35M |
| EBIT | -31.56B |
| Loss Per Share | -1,616.00 |
Balance Sheet
The company has 6.78 billion in cash and 216.12 billion in debt, with a net cash position of -209.33 billion or -11,413.42 per share.
| Cash & Cash Equivalents | 6.78B |
| Total Debt | 216.12B |
| Net Cash | -209.33B |
| Net Cash Per Share | -11,413.42 |
| Equity (Book Value) | 220.27B |
| Book Value Per Share | 12,019.48 |
| Working Capital | -63.67B |
Cash Flow
In the last 12 months, operating cash flow was 1.46 billion and capital expenditures -7.92 billion, giving a free cash flow of -6.46 billion.
| Operating Cash Flow | 1.46B |
| Capital Expenditures | -7.92B |
| Depreciation & Amortization | 31.79B |
| Net Borrowing | 2.36B |
| Free Cash Flow | -6.46B |
| FCF Per Share | -352.15 |
Margins
Gross margin is 25.52%, with operating and profit margins of -21.63% and -20.31%.
| Gross Margin | 25.52% |
| Operating Margin | -21.63% |
| Pretax Margin | -16.87% |
| Profit Margin | -20.31% |
| EBITDA Margin | 0.16% |
| EBIT Margin | -21.63% |
| FCF Margin | n/a |
Dividends & Yields
KRX:102460 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.17% |
| Shareholder Yield | 0.17% |
| Earnings Yield | -14.45% |
| FCF Yield | -3.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 29, 2020. It was a forward split with a ratio of 1.02.
| Last Split Date | Dec 29, 2020 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
KRX:102460 has an Altman Z-Score of 0.98 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.98 |
| Piotroski F-Score | 4 |